Skip to content Skip to footer

Pro Medicus Limited

Share Price and News

ASX BIG FOUR - LIVE SNAPSHOT

SELL

Whitehaven Coal

(ASX:WHC)

Paul Flynn
01/03/2026
$8.7m
BUY

Elixir Energy

(ASX:EXR)

Featured
SELL

Aspen Group

(ASX:APZ)

David Dixon
03/03/2026
$11.4m
BUY

Lovisa

(ASX:LOV)

Brett Blundy
04/03/2026
$6.8m
Copmany Overview

About Pro Medicus (ASX:PME)

Pro Medicus is an Australian business specialising in medical imaging technology. Founded and based in Melbourne, Victoria, in 1983, its Visage 7 software enables  hospitals and diagnostic imaging providers to efficiently manage and interpret large volumes of medical images. The platform is known for its speed, scalability, and native cloud architecture. The company has a strong presence in North America and is expanding its activities in Europe and other international markets. Its SaaS business model delivers high-margins and recurring revenue. These factors have meant the company has not had to raise capital and its share price has kept expanding and expanding as it continues to roll out into the US. Moreover,  The company’s software requires minimum capex to be installed or training for clients to use.

Pro Medicus Company History

The company was founded in Melbourne in 1983 by Dr Sam Hupert and Anthony Hall. Having recently graduated from medical school, the pair saw potential for the use of computers in medicine, even when computers were more complicated. Initially, it gained a foothold in healthcare IT through medical practice management software and later through helping patients receive diagnostic results faster. In 2000 it listed and managed to survive the dot com burst. It expanded overseas, including into North America through a deal with Agfa. In 2009, the company bought Visage Imaging, a German and U.S.-based imaging software firm that was then owned by Mercury Systems. It paid just US$3.5m. Following the acquisition, the company launched Visage 7, which became central to its product offerings and positioned Pro Medicus as a leader in medical imaging. Since then, client numbers have increased through long-term contracts with major health networks and leading academic hospitals in the US. 2014 was a key year when it unveiled a six-year deal worth $20m with a large US health network. The deals have kept flowing since then, but that first one was major because PME won out of nearly 30 companies (including majors like GE, Phillips and Siemens). The rest is history. In FY24, Pro Medicus generated $161.5m in revenue and an $82.8m profit, representing a near 50% margin. Its biggest deal in that year was a 10-year US$140m deal with Baylor Scott & White.

Get Our Full ASX Stock Analysis Report

Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.

Forward View

Future Outlook of Pro Medicus (ASX: PME)

Pro Medicus is well-positioned amid an ever-growing market. Despite having A$624m in contracts over 5 years assuming current contracts up for renewal are renewed, the company claims it has only penetrated 7% of the market and that it is growing by 3.5% per year. Moreover, it claims that it could benefit from adopting AI in its software, and expanding it to other health services using medical imaging, such as cardiology. The key risks are competition, key personnel risk and macroeconomic risks. That said, as advances in medical imaging continue, the data required keeps expanding.  For example, an optoacoustic breast ultrasound can take up more than 10 GB of computer storage. This means downloading images, and in turn viewing them, can take a while and waiting reduces radiologists’ productivity. And in a post-COVID world, with even doctors now working from home, you don’t want you images just sitting on one computer in an office somewhere.

Our Assessment

Is PME a Good Stock to Buy?

Pro Medicus has consistently delivered strong returns, making it one of the most closely watched technology stocks on the ASX. Its financial performance is supported by long-term contracts, high margins, and a recurring revenue model tied to imaging volumes from some of the top hospitals globally. That said, its valuation is demanding, trading at a high price-to-earnings multiple relative to the broader market. This suggests the market has priced in a significant portion of future growth. Investors should weigh this premium against the company’s strong fundamentals, debt-free balance sheet, and impressive growth pipeline. For growth-focused investors comfortable with tech-sector volatility, PME remains a quality business with strong fundamentals and global appeal.

Our Stock Analysis

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Knowing how to read a balance sheet is a key skill investors need to know,…

Adisyn (ASX:AI1) Graphene Breakthrough, What Investors Need To Know

Adisyn may have a fix for the Chip Industry's Wiring Problem Think about the wiring…

NEXTDC (ASX:NXT) Record 667MW Contracted & A$2.2B Capital Plan

S4 hits 71% contracted as utilisation jumps 60% to 667MW NextDC (ASX:NXT) has added 250MW…

TSMC’s (NSDQ:TSM) Money Printer, March Revenue $13.1B, Margins Hit 58%

Record Margins, AI Demand Still Accelerating TSMC (NSDQ:TSM) continues to show real pricing power. Demand…

ASML (NASDAQ:ASML) Q1 sales +15%, but system shipments slowed and stock fell 7%

Net orders beat revenue 1.2x, yet investors punished machine sales ASML (NASDAQ:ASML) sits at the…
Faq

Frequently Asked Questions

What does Pro Medicus do?
Pro Medicus provides advanced radiology imaging software through its flagship Visage 7 platform, used by hospitals and diagnostic groups to manage and analyse medical images.
Yes. Pro Medicus reported strong growth in FY24, with double-digit increases in both revenue and profit. The company continues to sign new contracts and expand its client base.
Yes. The company pays fully franked dividends and has increased payouts in line with earnings growth while retaining sufficient cash for reinvestment.
PME trades at a high valuation, reflecting strong investor confidence. While some view it as expensive, others believe its consistent growth and long-term contracts justify the premium.
Key risks include high valuation, dependence on the U.S. market, potential changes in healthcare spending, and competition from other imaging technology providers.

Stay Sharp on the ASX

Weekly research. Independent analysis. No noise.

Free forever · Unsubscribe anytime

Stocks Down Under (Pitt Street Research AFSL 1265112) provides actionable investment ideas on ASX-listed stocks. This content provides general information only and does not constitute financial advice. Always do your own research before making investment decisions. © 2026 Stock Down Under. All Rights Reserved.

© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here